Clinical Trials Directory

Trials / Completed

CompletedNCT01270867

Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke

Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
178 (actual)
Sponsor
Stryker Neurovascular · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

To determine if the Trevo Retriever is as good or better than the Merci Retriever in restoring blood flow to the brain of a patient experiencing an acute ischemic stroke in a large vessel.

Detailed description

The TREVO 2 protocol was designed to assess the safety and effectiveness of the Trevo Retriever device and determine if it is substantially equivalent to the predicate Merci Retriever. The trial utilized a Primary Effectiveness Endpoint of revascularization and a composite Primary Safety Endpoint that included procedure-related serious adverse events occurring within 24 hours of the procedure. Subjects who presented to enrolling centers with large ischemic strokes were screened for eligibility in the study. If a subject met eligibility criteria, then Informed Consent was obtained prior to commencing the angiogram. If all inclusion/exclusion criteria were confirmed, including the angiographic criteria, then the subject was randomized.The Primary Effectiveness Endpoint was successful revascularization of the target occlusion, using the TICI score. Success was determined by the central Core Lab.The Primary Safety Endpoint is a composite endpoint, described in the protocol as the "Incidence of procedure-related serious adverse events (PRSAEs) through 24 hours post procedure (-6/+12 hours) defined as: vascular perforation or intramural arterial dissection, symptomatic ICH, embolization to a previously uninvolved territory, access site complication requiring surgical repair or blood transfusion, intra-procedural mortality, device failure (in vivo breakage), or any other complications judged by the Clinical Events Committee (CEC) to be related to the procedure."

Conditions

Interventions

TypeNameDescription
DEVICEMechanical ThrombectomyEach arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.

Timeline

Start date
2011-02-01
Primary completion
2011-12-01
Completion
2012-03-01
First posted
2011-01-05
Last updated
2015-08-03
Results posted
2014-02-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01270867. Inclusion in this directory is not an endorsement.